Secukinumab for patients failing previous TNF α-inhibitor therapy: results of a randomised open-label study (Signature).

CONCLUSIONS: This study provides evidence of efficacy and safety of secukinumab for treatment of psoriasis patients who failed prior TNFα-inhibitor therapy. This study represents a 'real world' population, providing reassurance that secukinumab is a treatment option in this difficult-to-treat population.
PMID: 31628677 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - October 17, 2019 Category: Dermatology Authors: Warren RB, Barker J, Finlay AY, Burden AD, Kirby B, Armendariz Y, Williams R, Hatchard C, Khare S, Griffiths CEM Tags: Br J Dermatol Source Type: research